Introduction &
Pyruvate dehydrogenase (PDH) is an essential rate-limiting enzyme connecting glycolysis with the tricarboxylic acid cycle and oxidative phosphorylation [16] . PDH defi ciency is heterogeneous both clinically and at the biochemical and molecular levels. Most PDH complex defi ciencies result from mutations in the X-linked E1 subunit gene ( PDHA1 ). Clinical presentations range from fatal neonatal lactic acidosis to chronic nonprogressive encephalopathy [15, 16] . recurrent episodes of acute isolated ataxia in infancy. Both had normal blood and CSF lactate levels. Although symptoms initially resolved between episodes during the fi rst decade, both patients subsequently worsened and developed progressive and severe encephalopathy, leading to death in their twenties. The spectrum of intermittent presentations in PDH defi ciency includes episodic ataxia, intermittent peripheral weakness, recurrent dystonia and extrapyramidal movement disorders. Conclusions: PDH defi ciency should be considered in patients with unexplained intermittent and recurrent acute neurological symptoms. Long-term prognosis and outcome remain uncertain. PDH defi ciency can occur even with normal CSF lactate concentration.
MRI revealed focal hyperintensities in the perisylvian cortex and the brain stem. Respiratory chain and PDH activities mea sured in fi broblasts revealed PDH defi ciency. Thereafter, he had persistent truncal ataxia, unsteadiness of gait and his neurological status progressively worsened. Thiamine was administered at age 10 years (150 mg daily) without clinical effect. At age 11 years, he had lost the ability to walk. His speech was dysarthric and he developed swallowing disturbances. In the following years, he continued to deteriorate, presenting seizure, tremor, left hemiparesis followed by progressive spastic tetraparesis. Ketogenic diet was tried for several months without improvement. Evolution was marked by severe central hypoventilation requiring tracheostomy and chronic ventilation until death at age 20 years. Patient 2 was the younger brother of patient 1. Perinatal period and early development were normal. He walked unaided at 12 months. A few weeks later, parents noticed unsteady gait and he stopped walking until 18 months. At 3 years, he presented acute ataxia after a viral infection. Over two weeks, he completely recovered. Another ataxic episode recurred six months later. PDH defi ciency was diagnosed. He continued to present recurrent ataxic episodes (twice a year) separated by symptom-free periods. Lactate in blood and CSF was 1.18 mmol / L and 1.41 mmol / L, and L / P ratio, 22.1 and 18.5, respectively. He received thiamine (250 mg / day) but progressively deteriorated after age of 10 years, developing seizure, dysarthria, tremor, spastic tetraparesis and severe encephalopathy, leading to death at age 21 years.
Methods &
PDH activities in the native and dichloroacetate-activated states and PDH subunit activities were measured in cultured fi broblasts as described [18] . An E1 mutation was detected by cDNA amplifi cation and sequencing as described [4] . The PCR primers were PDHE1 -F, 5 Ј -CTCCTGGGTTGTGAGGAGTC-3 Ј and PDHE1 -R, 5 Ј -TGGTAGCCCCCTGAAGCTAT-3 Ј (T a 55 ° , 1248-bp amplicon); PDH2 / 3-F, 5 Ј -CAGGGTGGAAGAGAAGCCTA-3 Ј and PDH2 / 3-R, 5 Ј -CCACCACAAACCTACCACTC-3 Ј (T a 54 ° , 965-bp amplicon); PDH7-F, 5 Ј -AGCCAAATGAAACCCCTTTT-3 Ј and PDH7-R, 5 Ј -AATGTCA-CTACGGGAGACGTG-3 Ј (T a 54 ° , 210-bp amplicon). Biochemical and molecular studies were performed with informed consent of patients or their legal guardians. We examined available clinical data in reported PDH defi cient patients presenting with intermittent ataxia, using Medline database searches.
Results

&
Results of enzyme studies performed in fi broblasts are shown in ᭹ ᭤ Table 1 . Molecular studies revealed a single base pair substitution 585 G>C in the PDHA1 gene in both patients. Clinical features of reported PDH-defi cient patients initially presenting with intermittent ataxia are summarized in ᭹ ᭤ Table 2 [1, 2, 9, 10, 12 -15] . We report the long-term follow-up of two brothers with PDH defi ciency initially presenting with recurrent episodes of isolated acute ataxia with complete recovery between episodes. An important clue for the suspicion of PDH or respiratory chain defi ciencies is a raised lactate concentration in blood. Nevertheless, blood lactate can be normal in some PDH-defi cient patients, whereas being typically elevated in CSF [3] . We report to the best of our knowledge, the fi rst cases of biochemically and molecularly proven PDH-defi cient patients with normal lactate levels in CSF, underlining that PDH defi ciency should be considered even in the absence of increased CSF lactate concentration. In PDH defi ciency, the L / P molar ratio is typically low, consistent with an unimpaired cytoplasmic redox state [16] . Paradoxally, our patient 1 had a mildly elevated L / P ratio in blood and CSF. The discriminant power of the L / P ratio was shown to increase at higher lactate concentrations, and this case illustrates the lack of signifi cance of the L / P ratio when lactate is in the normal range [6] . PDH defi ciency is clinically heterogeneous. A small subset of patients presents with an atypically mild course, with intermittent neurological symptoms often triggered by infectious illness. This phenotype is incompletely characterized, poorly emphasized in the medical literature, and possibly underdiagnosed. Blass et al. fi rst reported in 1970 an intermittent movement disorder in PDH defi ciency [2] . Since this description, only a handful of patients were reported for which intermittent ataxia was the presenting feature ( ᭹ ᭤ Table 2 ). Notably, all were male. Median age at fi rst ataxic event was 18 months. Frequency of episodes ranged from once a month to once a year. Remarkably, 5 / 12 patients showed a late-onset progressive neurodegenerative course. In contrast, 6 / 12 were cognitively unimpaired at last follow-up (median age: 8 years). Many patients with intermittent ataxia have presented in their clinical course some signs of basal ganglia or brainstem dysfunction: hyperventilation, dysarthria, dystonia or choreoathetosis ( ᭹ ᭤ Table 2 ). Although these symptoms initially resolved between episodes, it suggests a continuum in the disease severity spectrum, ending with typical Leigh syndrome. In addition to intermittent ataxia, recurrent acute dystonia [7] , episodic peripheral weakness sometimes mimicking GuillainBarre syndrome [5, 19] , and complex extrapyramidal movement disorders in adults [11] were more recently recognized in PDH defi ciency. This stresses the necessity to consider PDH defi ciency in any patient with unexplained recurrent acute neurological symptoms, even in the absence of chronic neurological impairment. Importantly, PDH defi ciency can be improved by specifi c treatment: thiamine, ketogenic diet and dichloroacetate [16] . The cG585C mutation in the PDHA1 gene, although briefl y mentioned in a summary table [4] , has never been observed in any other patient. It predicts the replacement of a highly conserved glycine to alanine (G195A). Although this change affects the thiamine pyrophosphate binding domain (TPP-BD), thiamine failed to improve our patients. Currently, 6 other mutations are known in the E1 -TPP-BD: A199 T, M210 V, W214R, P217L, F205L, L216F [8, 13] . Only the last two were thiamineresponsive in vivo . In contrast, several mutations outside the TPP-BD were thiamine-sensitive [8, 14] . Because the dimer of -E1 subunits is held together by TPP, it undoubtedly functions to stabilize the 2 2 complex, even when mutations are outside the TPP-BD. Indeed, mutations outside this site allow for normal TPP binding, stabilizing the protein. For example, thiamine responsiveness was demonstrated for a patient with the three C-terminal amino acids truncated [17] . Probably G195A in the TPP-BD precludes this stabilization from occurring. In practice, thiamine should be tried in all PDH-defi cient patients. Those with milder phenotypes (i.e., intermittent presentations) and higher residual enzyme activity are more susceptible to be thiamine-responsive. In summary, we report two patients with PDH defi ciency presenting with recurrent episodes of isolated acute ataxia. This unusual mode of presentation highlights the phenotypic variability in PDH defi ciency. Although only few patients were described in the literature, the occurrence of other types of intermittent neurological symptoms (including episodic weakness, acute dystonia and choreoathetosis) suggests that intermittent presentation could be an underestimated and underdiagnosed phenotype of PDH defi ciency. PDH defi ciency should be considered in patients with unexplained recurrent acute neurological symptoms.
